Jim Tananbaum – The Startup Health Tech Company: Mindstrong Health Gets $14 Million Funding

Mindstrong Health is a startup organization focused on applying Smartphone to aid and diagnose in treating neuropsychiatric disorders. The organization received $14 million in Series-A financing from investors such as Optum Ventures, One Mind Brain Health Impact Fund, ARCH Venture Partners and Foresite Capital among others. See, http://www.massdevice.com/neuropsych-treatment-diagnosis-platform-dev-mindstrong-health-raises-14m-series/.

All conventional medicine is founded on objective measurement but tracking mental health has been restricted to subjective analysis in a clinical environment as said by the CEO and Founder of Mindstrong Health. Jim Tananbaum also added that to enhance results for people suffering from mental disorders, we require the type of objective measures applied for other chronic diseases such as heart disease and diabetes. The technology in Mindstrong delivers objective measure, continuous and cognition at a resolution level and insight that is not possible.

Mindstrong has established a stage that utilizes patients’ patterns of typing and scrolling on smartphones to measure their brain function. The platform offers information concerning the cognition and mood biomarkers which entail function, memory and processing speed. The institution founding team brings great comprehending of the big challenges enveloping the manner in which the medical society takes care of the patients who suffer from cognitive health disorders.

Tananbaum is also the Founder and CEO of Foresite Capital an organization with $1 billion of resources under management. Jim has over 20 years’ experience building and investing healthcare companies, says ideamensch.com. Before he started Foresite Capital, he co-founded the two leading biopharmaceutical organizations and two healthcare investing practices. As he was completing Harvard Medical School, he commenced GelTex Pharmaceuticals which introduced two drugs into the market for a minimal of $80 million. Today, the drugs generate over $1 billion in revenues.

According to Market Wired, another organization that Tananbaum founded is the Theravance, Inc which he was also the CEO. Together with Theravance Biopharma, Inc, they have a total market cap of $2.75 billion. Tananbaum is a graduate of Yale with B.S.S and B.S.E.E. He also graduated from Harvard Medical School and pursued an M.D. and from Harvard Business School where he studied M.B.A and B.S. Jim Tananbaum also served on advisory boards and visiting committees to the Yale’s President Advisory Counsel and Harvard-MIT HST program.

Leave a Reply

Your email address will not be published. Required fields are marked *